Vimarsana
Biggest News Aggregation in the World

Malte Peters News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Malte Peters. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Malte Peters Today - Breaking & Trending Today

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization -January 16, 2024 at 07:02 am EST - Vimarsana News

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization -January 16, 2024 at 07:02 am EST

NEW YORK and VIENNA, Austria, Jan. 16, 2024 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the...

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results - Vimarsana News

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results - Vimarsana News

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results 16.11.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 16, 2022 MorphoSys AG...

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monj - Vimarsana News

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monj

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS...

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL - MorphoSys (NASDAQ:MOR) - Press Release - Vimarsana News

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL - MorphoSys (NASDAQ:MOR) - Press Release

The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth Annual Meet